Literature DB >> 12907156

Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations.

Paul Escarpe1, Nathalie Zayek, Peggy Chin, Flavia Borellini, Romain Zufferey, Gabor Veres, Veronique Kiermer.   

Abstract

Lentiviral vectors have demonstrated great potential as gene therapy vectors mediating efficient ex vivo and in vivo gene delivery and long-term transgene expression in both dividing and nondividing cells. However, for clinical studies it must be demonstrated that lentiviral vector preparations are safe and not contaminated by replication-competent recombinants related to the parental pathogenic virus. Here we describe a sensitive assay for the detection of replication-competent lentiviruses (RCL) in large-scale preparations of HIV-based lentiviral vectors. This RCL assay for lentiviral vectors is based on the principles used for retroviral vectors, using a highly permissive cell line, C8166-45, for RCL amplification and an appropriate positive control virus to establish the assay sensitivity. The assay is capable of detecting 1 RCL infectious unit in a background of 2.5 x 10(8) transducing units of vector in a single test culture. Statistically representative samples from large-scale lentiviral vector productions were assayed using multiple test cultures for each lot. Overall, a total of 1.4 x 10(10) transducing units of vector from 10 independent 14-liter production lots were screened and no RCL was detected. We propose to implement this assay as a release testing for clinical-grade lentiviral vector preparations intended for gene therapy clinical trials.

Mesh:

Year:  2003        PMID: 12907156     DOI: 10.1016/s1525-0016(03)00167-9

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  24 in total

1.  Overexpression of the pituitary tumor transforming gene induces p53-dependent senescence through activating DNA damage response pathway in normal human fibroblasts.

Authors:  Yi-Hsin Hsu; Li-Jen Liao; Chuan-Hang Yu; Chun-Pin Chiang; Jing-Ru Jhan; Lien-Cheng Chang; Yann-Jang Chen; Pei-Jen Lou; Jing-Jer Lin
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

Review 3.  Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.

Authors:  Ronald J Mandel; Corinna Burger; Richard O Snyder
Journal:  Exp Neurol       Date:  2007-08-24       Impact factor: 5.330

Review 4.  Evidence-based biosafety: a review of the principles and effectiveness of microbiological containment measures.

Authors:  Tjeerd G Kimman; Eric Smit; Michèl R Klein
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

5.  Biosafety in ex vivo gene therapy and conditional ablation of lentivirally transduced hepatocytes in nonhuman primates.

Authors:  Olivier Menzel; Jacques Birraux; Barbara E Wildhaber; Caty Jond; Françoise Lasne; Walid Habre; Didier Trono; Tuan H Nguyen; Christophe Chardot
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

6.  Assessment of hazard risk associated with the intravenous use of viral vectors in rodents.

Authors:  Jon D Reuter; Xiaoqun Fang; Christina S Ly; Karen K Suter; Daniel Gibbs
Journal:  Comp Med       Date:  2012-10       Impact factor: 0.982

7.  Enhanced genetic modification of adult growth factor mobilized peripheral blood hematopoietic stem and progenitor cells with rapamycin.

Authors:  Lijing Li; Mónica Torres-Coronado; Angel Gu; Anitha Rao; Agnes M Gardner; Elizabeth W Epps; Nancy Gonzalez; Chy-Anh Tran; Xiwei Wu; Jin-Hui Wang; David L DiGiusto
Journal:  Stem Cells Transl Med       Date:  2014-08-08       Impact factor: 6.940

8.  Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.

Authors:  Katherine T Marcucci; Julie K Jadlowsky; Wei-Ting Hwang; Megan Suhoski-Davis; Vanessa E Gonzalez; Irina Kulikovskaya; Minnal Gupta; Simon F Lacey; Gabriela Plesa; Anne Chew; J Joseph Melenhorst; Bruce L Levine; Carl H June
Journal:  Mol Ther       Date:  2017-10-20       Impact factor: 11.454

9.  Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Authors:  Kenneth Cornetta; Lisa Duffy; Cameron J Turtle; Michael Jensen; Stephen Forman; Gwendolyn Binder-Scholl; Terry Fry; Anne Chew; David G Maloney; Carl H June
Journal:  Mol Ther       Date:  2017-09-12       Impact factor: 11.454

10.  Development of an equine-tropic replication-competent lentivirus assay for equine infectious anemia virus-based lentiviral vectors.

Authors:  Daniel C Farley; Richard Bannister; Marie A Leroux-Carlucci; Nerys E Evans; James E Miskin; Kyriacos A Mitrophanous
Journal:  Hum Gene Ther Methods       Date:  2012-11-02       Impact factor: 2.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.